l General Information |
Product Name | TAK-875 |
General description | Fasiglifam(TAK-875) is a selective GPR40 agonist. |
Synonym | 2-[(3S)-6-[[3-[2,6-dimethyl-4-(3-methylsulfonylpropoxy)phenyl]phenyl]methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid; Fasiglifam; TAK875; TAK 875; |
Purity | ≥98%(HPLC) | CAS Number | 1000413-72-8 |
Formula | C29H32O7S | Molecular Weight | 524.628 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or Off-white solid |
Solubility(25℃) | DMSO | ≥50mg/mL |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Fasiglifam has been used in trials studying the treatment of Chronic Kidney Disease, Type 2 Diabetes Mellitus, and Diabetes Mellitus, Type 2. |
l Packaging & Storage |
Packaging | 5mg; 25mg; 250mg |
Storage temp. | -20℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
